Shenzhen Kangtai Biological Products Co Ltd (300601) — Working Capital to Net Assets Ratio
Shenzhen Kangtai Biological Products Co Ltd (300601) has a Working Capital to Net Assets ratio of 43.2% as of June 2026. Working capital of CN¥4.17 Billion (current assets of CN¥6.21 Billion minus current liabilities of CN¥2.03 Billion) is measured against net assets of CN¥9.66 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See operational self-sufficiency of Shenzhen Kangtai Biological Products Co to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Shenzhen Kangtai Biological Products Co Ltd Working Capital to Net Assets (2012–2025)
This chart shows how Shenzhen Kangtai Biological Products Co Ltd's Working Capital to Net Assets ratio has evolved across 14 annual periods from 2012 to 2025. As of June 2026, the ratio stands at 43.2%, reflecting working capital of CN¥4.17 Billion against net assets of CN¥9.66 Billion CNY. For the complete balance sheet picture, see 300601 current and non-current assets.
Annual Working Capital to Net Assets for Shenzhen Kangtai Biological Products Co Ltd (2012–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Shenzhen Kangtai Biological Products Co Ltd from 2012 to 2025, covering 14 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check 300601 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 39.2% | CN¥3.78 Billion | CN¥9.63 Billion | CN¥5.99 Billion | CN¥2.22 Billion | ▲ +2.0 pp |
| 2024 | 37.2% | CN¥3.60 Billion | CN¥9.66 Billion | CN¥6.24 Billion | CN¥2.65 Billion | ▲ +9.5 pp |
| 2023 | 27.7% | CN¥2.64 Billion | CN¥9.54 Billion | CN¥5.40 Billion | CN¥2.75 Billion | ▼ -3.8 pp |
| 2022 | 31.6% | CN¥2.84 Billion | CN¥8.99 Billion | CN¥5.17 Billion | CN¥2.34 Billion | ▼ -20.0 pp |
| 2021 | 51.5% | CN¥4.72 Billion | CN¥9.17 Billion | CN¥7.34 Billion | CN¥2.62 Billion | ▲ +3.4 pp |
| 2020 | 48.1% | CN¥3.59 Billion | CN¥7.46 Billion | CN¥5.34 Billion | CN¥1.76 Billion | ▲ +13.3 pp |
| 2019 | 34.8% | CN¥958.02 Million | CN¥2.75 Billion | CN¥1.83 Billion | CN¥870.18 Million | ▼ -7.2 pp |
| 2018 | 42.0% | CN¥770.83 Million | CN¥1.84 Billion | CN¥1.74 Billion | CN¥974.02 Million | ▲ +22.1 pp |
| 2017 | 19.9% | CN¥213.20 Million | CN¥1.07 Billion | CN¥989.68 Million | CN¥776.48 Million | ▼ -3.3 pp |
| 2016 | 23.2% | CN¥170.47 Million | CN¥735.00 Million | CN¥579.81 Million | CN¥409.34 Million | ▲ +0.6 pp |
| 2015 | 22.6% | CN¥146.24 Million | CN¥647.12 Million | CN¥461.17 Million | CN¥314.94 Million | ▼ -12.3 pp |
| 2014 | 34.9% | CN¥203.71 Million | CN¥583.81 Million | CN¥548.89 Million | CN¥345.18 Million | ▲ +4.0 pp |
| 2013 | 30.9% | CN¥114.91 Million | CN¥372.17 Million | CN¥379.80 Million | CN¥264.89 Million | ▼ -37.6 pp |
| 2012 | 68.5% | CN¥295.37 Million | CN¥431.21 Million | CN¥456.99 Million | CN¥161.62 Million | — |